Abstract
The characterization of molecular changes in diseased tissues gives insight into pathophysiological mechanisms and is important for therapeutic development. Genome-wide gene expression analysis has proven valuable for identifying biological processes in neurodegenerative diseases using post mortem human brain tissue and numerous datasets are publically available. However, many studies utilize heterogeneous tissue samples consisting of multiple cell types, all of which contribute to global gene expression values, confounding biological interpretation of the data. In particular, changes in numbers of neuronal and glial cells occurring in neurodegeneration confound transcriptomic analyses, particularly in human brain tissues where sample availability and controls are limited. To identify cell specific gene expression changes in neurodegenerative disease, we have applied our recently published computational deconvolution method, population specific expression analysis (PSEA). PSEA estimates cell-type-specific expression values using reference expression measures, which in the case of brain tissue comprises mRNAs with cell-type-specific expression in neurons, astrocytes, oligodendrocytes and microglia. As an exercise in PSEA implementation and hypothesis development regarding neurodegenerative diseases, we applied PSEA to Parkinson's and Huntington's disease (PD, HD) datasets. Genes identified as differentially expressed in substantia nigra pars compacta neurons by PSEA were validated using external laser capture microdissection data. Network analysis and Annotation Clustering (DAVID) identified molecular processes implicated by differential gene expression in specific cell types. The results of these analyses provided new insights into the implementation of PSEA in brain tissues and additional refinement of molecular signatures in human HD and PD.
Introduction
Identifying changes in gene or protein expression has the potential to focus attention on key molecular mechanisms underlying a given degenerative process (e.g., disease or aging effects on the brain). Genome wide expression studies using microarrays and next generation sequencing (NGS) technologies have been widely adopted to identify gene expression changes in human post mortem tissue for a number of neurodegenerative diseases. However, neurodegenerative diseases often lead to progressive changes in brain parenchyma composition, typically comprising a decline in the number of neuronal cells, together with an increase of glial cell number (astrocytes, oligodendrocytes and/or microglia) (Figure 1). These changes in the relative proportions of different cell populations can confound the ability to detect the molecular changes occurring in specific cell types. Therefore, when analyzing genome wide expression data from central nervous system (CNS) tissues it is important to use methods that can reliably account for changes in cell numbers to allow correct interpretations.
Figure 1
To overcome this problem, we have recently developed a method called Population-Specific Expression Analysis (PSEA) and shown its potential to successfully identify novel gene expression changes in human HD caudate (Kuhn et al., ). The method deconvolves brain expression heterogeneity by linear regression modeling to resolve cell-type-specific expression changes. We therefore reasoned that implementation of PSEA has the potential to create new, improved analyses of other brain datasets describing neurodegenerative processes.
Here we applied the PSEA method on publically available genome wide expression data generated from human Huntington's disease (HD) motor cortex (Hodges et al., ) as well as Parkinson's disease (PD) datasets derived from human prefrontal cortex, putamen and substantia nigra tissues (Zhang et al., ). Differentially expressed genes were analyzed for their inclusion in co-regulated gene networks, protein-protein interactions (PPIs) and memberships within identified functional networks to identify biological processes that may underlie disease-related effects. These analyses reinforced the robustness of the method and identified potential genes and pathways for further study.
Materials and methods
Microarray gene expression data
In the present study, we applied PSEA and standard differential expression analyses to HD brain mRNA expression data from frontal cortex (BA4) samples (16 control and 18 HD brains) (Hodges et al., ), and to PD brain expression data from prefrontal cortex (15 control and 14 PD), substantia nigra (18 control and 11 PD) and putamen (15 control and 20 PD) (Zhang et al., ). Microarray data sets were downloaded from Gene Expression Omnibus (Barrett et al., ) (GSE3790 for HD and GSE20295 for PD) (http://www.ncbi.nlm.nih.gov/geo/). These data were generated on Affymetrix Human microarrays U133A (HD, PD) and U133B (HD only). Probesets were annotated with current HUGO Gene Nomenclature Committee (HGNC) gene assignments using bioDBnet (Mudunuri et al., ) (http://biodbnet.abcc.ncifcrf.gov/db/db2db.php#biodb).
PSEA analyses
For a comprehensive review on the implementation of PSEA, see (Kuhn et al., ) and the PSEA R package (www.bioconductor.org). The initial step in the application of PSEA to the datasets was to select appropriate marker gene probesets for each brain cell population (neurons, astrocytes, oligodendrocytes and microglia) (Kuhn et al., , ). Marker genes were selected based upon prior evidence of cell-type-restricted expression in the literature and previous implementation of PSEA in HD (Kuhn et al., ). We verified that the signals corresponding to different probesets representing the same cell population were highly correlated (mean correlation >0.5), and conversely, that the signals of the marker gene probesets representing the other cell populations were poorly correlated (mean correlation <0.05). The probesets used as reference expression signals for each cell type and dataset were as follows. For HD BA4 cortex, neurons: 221805_at (NEFL), 221801_x_at (NEFL), 221916_at (NEFL), 201313_at (ENO2), 210040_at (SLC12A5), 205737_at (KCNQ2), 210432_s_at (SCN3A); astrocytes: 203540_at (GFAP), 210068_s_at (AQP4), 210906_x_at (AQP4), 201667_at (GJA1), oligodendrocytes: 211836_s_at (MOG), 214650_x_at (MOG), 216617_s_at (MAG), 207659_s_at (MOBP), 207323_s_at (MBP), 209072_at (MBP); and microglia: 204192_at (CD37), 215051_x_at (AIF1), 209901_x_at (AIF1), 213095_x_at (AIF1). For PD prefrontal cortex, neurons: 221805_at (NEFL), 221801_x_at (NEFL), 221916_at (NEFL), 201313_at (ENO2), 210040_at (SLC12A5), 205737_at (KCNQ2); astrocytes: 203540_at (GFAP), 210068_s_at (AQP4), 210906_x_at (AQP4), 201667_at (GJA1); oligodendrocytes: 211836_s_at (MOG), 214650_x_at (MOG), 216617_s_at (MAG), 207323_s_at (MBP), 209072_at (MBP); and microglia: 215051_x_at (AIF1), 209901_x_at (AIF1), 213095_x_at (AIF1). For PD substantia nigra and putamen, neurons: 221805_at (NEFL), 221801_x_at (NEFL), 221916_at (NEFL), 201313_at (ENO2), 210040_at (SLC12A5), 205737_at (KCNQ2); astrocytes: 203540_at (GFAP), 210068_s_at (AQP4), 210906_x_at (AQP4), 201667_at (GJA1); oligodendrocytes: 211836_s_at (MOG), 214650_x_at (MOG), 216617_s_at (MAG), 207323_s_at (MBP), 209072_at (MBP); microglia: 215051_x_at (AIF1), 209901_x_at (AIF1), 213095_x_at (AIF1).
To calculate the reference expression signals for each cell type we proceeded as follows. First, the expression values of the selected probesets were normalized to an average value of 100 to give them an equal weight, and those reporting the same marker gene expression were then averaged to obtain a marker gene expression measure for each gene. Then we averaged the marker gene expression measures for each cell population to obtain a reference expression signal for each cell population for each sample.
The next step was to fit candidate multiple regression models for the data for all probesets. Using the Akaike information criterion (AIC) (Akaike, ), we selected the best model for each probeset in terms of the regressors to be included from the set of reference signals corresponding to the 4 cell populations considered. In this way, we obtained models with 1–4 regressors that were then tested for quality of fit. The criteria used were the following: F-test (p < 0.05), adjusted R squared >0.6 and Shapiro test for a Gaussian distribution of the residuals (p > 0.01). In addition, models with large intercepts (absolute value larger than half of the mean expression value of the probeset) or negative coefficients were excluded. The probesets comprising the reference expression signals were also removed from the final tables.
In order to test for differential expression between control and disease samples we added one auxiliary regressor to each of the selected models. This regressor was formed by a vector having zeros in all positions except for the ones of the disease samples corresponding to the interrogated cell type. The auxiliary regressors were added one at a time to assess the specific expression of each cell type included in the model. For each cell type, the regressor coefficient represents the specific expression in the control group, while the coefficient of the auxiliary regressor estimates the differential expression and the specific expression in the disease is determined as the sum of both. The quality of the models including the auxiliary variable was then re-assessed as explained above. Finally, we constructed a table showing the multiple regression results of the probesets ordered by the p-values of the differential expression, including only cases with p < 0.05. The PSEA was implemented using a customized R script (Gentleman et al., ) using the functions lm and stepAIC.
An alternative approach to select the multiple regression models was applied in tissues where the simultaneous modeling of expression in the four cell types was hampered by poor correlations of the expression reported by the astrocyte and oligodendrocyte reference probesets (see below). In these cases, we restricted our analyses to probesets that reported expression exclusively in a single cell type, so as to avoid misassignment of differential expression. Single cell type expression was assigned by computing the correlation between each probeset and the reference signals and restricting further analyses to the cases where the correlation was larger than 0.8 for a single cell type (e.g., neurons) and less than 0.2 for the other three cells types (e.g., astrocyte, oligodendrocyte and microglia). We then calculated regressions with only one cell-type regressor (neurons in the above example) plus the corresponding auxiliary regressor (for differential expression between disease and control). The models obtained in this way were tested for quality of fit in the same manner explained above for the models selected with AIC, and tables to show the differential expression results were constructed. This approach proved useful in cases where the probes typically used to create the reference expression signals showed poor correlation between them (as was observed for astrocyte and oligodendrocyte signatures in the PD substantia nigra and putamen data sets) because it allowed us to nonetheless apply the PSEA to the cell types that have good quality reference expression signals (neurons and microglia in this example). The disadvantage of this approach is that we are unable to make interpretations regarding the differential expression of genes that are expressed in multiple cell types or in the cell types with poorly correlated probesets comprising the reference expression signals (here, astrocytes and oligodendrocytes). As a way to validate the approach, we compared the performance of both strategies in selecting models using PD prefrontal cortex, which has good reference signals and a large number of differentially expressed genes. This showed that 70% of the differentially expressed probes identified by the standard implementation of PSEA were also detected using the alternative approach.
Standard gene expression analysis
In order to evaluate the potential for PSEA to refine gene expression measures, we compared PSEA results to standard differential expression analyses performed with packages from Bioconductor (affy (Gautier et al., ) and limma (Smyth, )) (www.bioconductor.org). HD cortex analysis with limma identified 1925 differentially expressed (DE) probesets passing a fdr cutoff of p < 0.05, consistent with our previous analysis of these data (Hodges et al., ). For PD cortex, limma analysis identified 304 DE probesets passing a fdr cutoff of p < 0.05, whereas 91 probesets showed differential expression in the substantia nigra and only 1 probeset in the putamen by the same significance threshold criterion.
Validation of PSEA Assignment using cell specific expression data
Two independent, publically available genome-wide expression data sets examining mouse CNS cell type gene expression were used to evaluate PSEA-based expression predictions. These two datasets examined relative expression in three of the four CNS cell types examined in our the PSEA analyses (neurons, oligodendrocytes, astrocytes). One of the datasets employed subcultures of primary mouse brain cells to derive cell-type-specific expression profiles (Cahoy et al., ), of which we used profiles of postnatal day 16 neurons, postnatal day 17 astrocytes, and myelinating oligodendrocytes. The second data set employed translating ribosome affinity purification (TRAP) to mouse brain tissue to generate cell-type-specific expression profiles of different CNS cell types (Doyle et al., ), of which we used Ntsr1-positive cortical neurons, Aldh1L1-positive cortical astrocytes, and Cmtm5-positive cortical oligodendrocytes. Both datasets were generated using the Affymetrix Murine 430 plus 2.0 microarray platform. To compare our PSEA-based expression predictions from human tissues to the mouse data, murine probesets were annotated with current corresponding HGNC gene assignments using dbOrtho tool in bioDBnet (Mudunuri et al., ) and the list of probesets for which PSEA achieved suitable expression models (Tables S1, S2) were reduced to unique HGNC ids. Then for each assignment of expression in a particular cell type by PSEA, we tallied whether expression was detected in that cell type in the mouse datasets, using a threshold of >100 arbitrary normalized expression units.
Validation of PSEA differentially expressed genes in PD substantia nigra
PSEA results of DE in PD substantia nigra neurons were validated using additional microarray expression data. These data were published in three independent studies that used laser capture microdissection (LMD) to selectively sample substantia nigra neurons; the tissue samples in these studies were comparable in terms of patient cohort age and disease state to the samples used in the PSEA analysis. For each of the 8 genes identified as differentially expressed in substantia nigra by PSEA (p < 0.05) we determined if the gene was identified as significantly changed in the same direction in any of the three LMD data sets. For two of the LMD studies (Simunovic et al., ; Elstner et al., ) fold change and p-values from microarray gene expression analyses available as supplementary data with the original manuscript were used for comparison. DE results were not published for the third LMD data set (Middelton-1 dataset included in Zheng et al., ); therefore the raw microarray data was downloaded from Gene Expression Omnibus (accession number GSE20141) and we performed differential expression analyses by standard limma analysis to obtain the necessary statistics (Smyth, ). LMD p-values and fold changes for all three studies are tabulated for comparison against PSEA-determined values.
Functional annotation clustering
The David 2.0 Bioinformatics database was used to identify functionally related groups of DE genes in individual cell types (http://david.abcc.ncifcrf.gov/) (Huang Da et al., ; Sprooten et al., ). Panther and Reactome pathways were added to the default selected functional annotation and the functional annotation clustering tool was applied to the lists of probe sets. The classification stringency setting used was medium with default setting for function grouping except for enrichment thresholds for EASE which were reduced to 0.05 to reduce inclusion of non significant terms into the clusters. Annotation Clusters of significantly over represented groups with terms having a FDR <50% were accepted for further consideration.
Network analysis
Cytoscape was used to examine coregulation, cell type specific expression and PPI networks for DE genes. A HGNC database was downloaded in July 2014 (Gray et al., ) (http://www.genenames.org/) and imported into Cytoscape 2.8.3 (http://www.cytoscape.org/) (Smoot et al., ). Using HGNC gene symbols as the key ID, the HGNC network was then merged with a network of coregulated gene pairs computed from seven normal human cortex data sets (Mistry et al., ). Human PPIs for DE genes (proteins) within the selected network were retrieved from Biogrid on August 17th 2014 (http://thebiogrid.org/) (Stark et al., ). Publically available genome wide gene expression data of mouse CNS cell types was obtained as supplementary data (Doyle et al., ) and mapped onto the HGNC network after retrieving the current corresponding HGNC gene assignments using dbOrtho tool in bioDBnet (Mudunuri et al., ). Cytoscape App Multicolored nodes (Warsow et al., ) was employed to visualize cell specific expression data in specific molecular networks.
Results and discussion
The present analyses comprise a study in the implementation of PSEA within the International Neuroinformatics Coordinating Facility (INCF) Short Course on Neuroinformatics, Neurogenomics and Brain Disease held in 2013 (https://sites.google.com/site/neuroinformaticsjamboree), with a view toward assessing candidate mechanisms of human neurodegenerative diseases. The datasets used in the analyses presented here are publically available and derived from postmortem samples of human HD (Hodges et al., ) and PD brains (Zhang et al., ) (see Materials and Methods). These two conditions represent two functionally distinct disease-related perturbations to the motor output circuit involving the cerebral cortex and basal ganglia (Albin et al., ).
HD is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin (HD, ITI5) gene (The Huntingtons Disease Collaborative Research Group, ). The CAG repeat expansion encodes a polyglutamine stretch within the N-terminal domain of the huntingtin protein (Htt) that imparts neurotoxicity, mostly through gain-of-function mechanisms, including Htt protein aggregation, as has been recapitulated in animal studies (Bates et al., ). A recent report using the PSEA method corroborated previous mouse data by detecting myelin-related gene expression changes in HD oligodendrocytes, supporting the possibility that deficient myelin synthesis and/or composition changes may by drivers of disease in HD (Kuhn et al., ).
PD is a neurodegenerative disease that can have either a sporadic or a familial etiology (Block et al., ). PD is typified by specific loss of dopaminergic neurons of the substantia nigra pars compacta that project to the neostriatum (caudate nucleus and putamen) (Dickson, ). This degeneration leads to PD-related symptoms including bradykinesia, tremor, rigidity and postural instability (Dauer and Przedborski, ). At the cellular level, PD is characterized by α-synuclein protein aggregates in neuronal cells (also known as Lewy bodies). Genes associated with familial PD include the gene encoding α-synuclein (SNCA) and genes involved in protein turnover and mitochondrial homeostasis, such as PARK2, which encodes Parkin (Kumar et al., ).
Implementation of PSEA to identify differential expression within specific cell subpopulations in HD and PD brains
In the present study, we applied PSEA analyses to expression data derived from motor cortex (BA4) samples from 16 control and 18 HD brains, and to prefrontal cortex samples from 15 control and 14 PD brains. For these cortical samples, the PSEA expression models were selected with the approach described in (Kuhn et al., ; see Materials and Methods) to assign expression and analyze differential expression using a model representing four cell compartments (neurons, astrocytes, oligodendrocytes and microglia). The regressors used for each of these models are listed in Supplementary Tables S1, S2. For HD motor cortex, PSEA provided evidence of 14 genes differentially expressed in neurons, 6 in astrocytes, and 8 in oligodendrocytes (0 in microglia) (Table S3). For PD prefrontal cortex, PSEA identified differential expression of 122 genes in neurons, 5 in astrocytes, 11 in oligodendrocytes, and 11 in microglia (Table S4). There was very little overlap between the genes identified as DE in HD and PD cortex but, interestingly, both diseases shared down regulation of doublecortin-like kinase 1 (DCLK1), a multi-functional, neuronally expressed gene known to be involved in neuronal migration, retrograde transport, neuronal apoptosis and neurogenesis (Dijkmans et al., ).
When the same PSEA procedures were applied to the PD substantia nigra (18 control and 11 PD) and putamen (15 control and 20 PD) datasets, we observed that the expression signals for the probesets that we had previously used to represent astrocytes and oligodendrocytes did not exhibit good correlation. Therefore, an alternative approach was adopted to select the multiple regression models that could be fit to a single cell type (neurons or microglia only), to avoid relying on reference signals with poor correlations (see Materials and Methods). These analyses provided evidence for the differential expression of 8 genes in neurons in the substantia nigra (Table S5) and 11 genes in neurons in the putamen (Table S6). Interestingly, however, DCLK1 was again one of the genes identified as differentially expressed in neurons in the substantia nigra, and was thus detected as differentially expressed in three of four neuronal datasets.
External validation of assignment of cellular expression
We used publically available genome wide expression datasets to validate PSEA-based expression assignments. Comprehensive cell type expression data generated from human cells was not available so expression data from mouse models were used (see Materials and Methods Section “Validation of PSEA Assignment using Cell Specific Expression Data”). We were able to corroborate PSEA-assigned expressions for a very large fraction of genes for which a suitable four-cell-type expression model could be constructed (Table 1).
Table 1
| Disease | Cell type | Number of regressor probe sets | Number of unique HGNC IDS | Mouse HGNC homologs with expression > 100 | |
|---|---|---|---|---|---|
| Primary culture expression (Cahoy et al., ) | TRAP expression (Doyle et al., ) | ||||
| Huntington's disease cortex | Neuron | 282 | 267 | 81% (210/259) | 75% (193/259) |
| Astrocyte | 60 | 54 | 84% (43/51) | 73% (37/51) | |
| Oligodendrocyte | 194 | 179 | 80% (139/174) | 66% (115/174) | |
| Parkinson's disease cortex | Neuron | 261 | 254 | 78% (188/239) | 70% (167/239) |
| Astrocyte | 89 | 88 | 75% (62/83) | 64% (64/83) | |
| Oligodendrocyte | 68 | 65 | 67% (40/60) | 53% (32/60) | |
Supporting evidence for gene expression in specific cell types from publically available datasets.
PSEA assignments of gene expression in neurons, astrocytes and oligodendrocytes were verified using two independent, publically available mouse expression datasets (Cahoy et al., ; Doyle et al., ). For procedures, see Materials and Methods, Section Validation of PSEA assignment using cell specific expression data.
Comparison of PSEA and standard differential expression analyses
We subsequently compared the outputs of population-specific and standard expression analyses (limma) to assess the potential improvement of cellular resolution of DE using PSEA. (For reference, results of the limma analyses of the datasets are included as Table S7.) Example comparisons from the analyses of PD frontal cortex and substantia nigra are illustrated in Figure 2. In the left panels for each gene (mRNA) their neuron-assigned expression values are plotted against the neuron reference expression signals to visualize disease-related expression differences in the slopes of the linear regressions fitted to the individual sample datapoints (black for control, red for PD). The accompanying box plots show the uncorrected expression values (from limma). These plots indicate examples that distinguish true differential expression from the reduction in the overall numbers of neuronal cells [SV2B (Figure 2K)], cases where PSEA detects differential expression when standard analyses were equivocal [PPP3CB (Figure 2A), GUCY1B3 (Figure 2B), RGS7 (Figure 2C), SYNJ1 (Figure 2E), DNM3 (Figure 2G), NDUFS2 (Figure 2H), RGS4 (Figure 2I), DCLK1 (Figure 2J)] and examples where limma would mis-assign the trend for differential expression as decreased rather than increased in diseased vs. control neurons [LPCAT1 (Figure 2D), PAK7 (Figure 2F), and INPP5F (Figure 2L)].
Figure 2
Comparison of DE genes in substantia nigra with laser capture microdissection data
Due to the strong interest in the effect of PD on neuronal gene expression in the substantia nigra pars compacta, a number of independent data sets have been published using LMD to obtain neuron-specific microarray expression profiles from postmortem human tissue. Although LMD cannot entirely replicate the PSEA analysis because it is limited to sampling RNA profiles in the cell body, whereas neuronal RNAs can be transported from the soma for local translation in both dendrites and axons, it is nonetheless the most appropriate data available for comparison. Despite this limitation, 6 out of 8 genes detected as differentially expressed in substantia nigra neurons by PSEA (Table S5) were validated as DE in the same direction in at least 1 independent LMD PD study. Furthermore, 4 out of 8 DE genes were validated in 2 independent studies (Table 2). These data further support the accuracy of prediction of cellularly resolved DE by PSEA.
Table 2
| Gene symbol | PSEA analysis this study | Simunovic et al., | Elstner et al., | Zheng et al., | ||||
|---|---|---|---|---|---|---|---|---|
| p-value | Log fold change | p-value | Log fold change | p-value | Log fold change | p-value | Log fold change | |
| CHN1 | 6.10E-03 | −1.61 | < 0.01 | −2.63 | 3.79E-02 | −1.61 | ||
| NSF | 1.10E-02 | −0.44 | < 0.01 | −3.23 | 7.74E-03 | −1.15 | ||
| SV2B | 1.44E-02 | −0.87 | < 0.01 | −2.50 | 4.79E-02 | −1.20 | ||
| GABARAPL1 | 2.59E-02 | −0.73 | < 0.01 | −1.31 | 1.10E-02 | −1.31 | ||
| DCLK1 | 3.29E-02 | −0.90 | 6.95E-03 | −1.48 | ||||
| ATP6V1A | 3.58E-02 | −0.71 | < 0.01 | −3.33 | ||||
Validation of PSEA determined DE in neurons in substantia nigra in PD by comparision with three independent LMD studies.
Eight genes were identified as DE by PSEA and those that were also significantly DE in at least one independent study are included in the table. Fold changes and p-values obtained were from the published manuscript where possible (Simunovic et al., ; Elstner et al., ) or generated from re analysis of raw data (Zheng et al., ).
The genes identified by PSEA as decreased in expression in PD substantia nigra, and validated by independent LMD studies, namely, chimerin 1 (CHN1) N-ethylmaleimide-sensitive factor (NSF), Synaptic Vesicle Glycoprotein 2B (SV2B), GABA(A) receptor-associated protein like 1 (GABARAPL1), the proton-transporting lysosomal 70kDa protein ATPase subunit V1 subunit A (ATP6V1A), and DCLK1 comprise potential candidates for further investigation. The synaptic vesicle-associated protein encoded by NSF has been recently highlighted in another bioinformatics screen aimed at identifying novel therapeutic targets for PD that included a meta analysis of transcriptomic data (Karic et al., ). In addition, a recent GWAS study identified NSF as novel candidate PD susceptibility gene in an Ashkenazi Jewish population (Liu et al., ). SV2B was also decreased in HD cortex neurons and DCLK1 was decreased in both HD and PD cortex neurons, suggesting that these genes may be involved in common pathways impacting neuronal degeneration in HD and PD. GABARAPL1 is also decreased in PD putamen neurons and is a key gene in the regulation of autophagy (see below).
Interesting genes and pathways represented in the PSEA results
The largest numbers of differentially expressed genes identified by our PSEA analyses in both HD and PD brains were in neuronal cells, although differences were also found in other brain cell types (astrocytes, oligodendrocytes and microglia). Annotation cluster analyses of the PSEA results using DAVID (Huang Da et al., ) and network analysis, employing both coregulation and PPI data, identified a number of genes and biological processes that have been implicated in neurodegenerative diseases.
Functional annotation cluster analyses in HD brain highlight endosome and plasma membrane signaling pathways
Htt is known to have functions in protein trafficking, vesicle transport, and postsynaptic signaling that may be altered by the HD-causing mutation (Gil and Rego, ). DAVID analyses of the genes detected as DE in HD neurons identified enrichment in genes related to vesicular transport and protein localization (Table 3, Annotation cluster 2). These included the endosomal Ras-related protein Rab-9B GTPase (RAB9B), syntaxin 1B (STX1B), the secretory carrier membrane protein 5 (SCAMP5), and the coiled-coil domain containing protein 91 (CCDC91). Interestingly, we have previously observed DE of RAB9B in a mouse model of HD (Tang et al., ). STX1B is essential for the regulation of spontaneous and evoked synaptic vesicle exocytosis (Mishima et al., ) and has been associated with PD in GWAS studies (Pihlstrom et al., ). SCAMP5 is involved in vesicle endocytosis (Zhao et al., ) and has been associated with autism (Castermans et al., ). CCDC91 is thought to be involved in white matter development and maintenance (Sprooten et al., ).
Table 3
David functional annotation clustering with differentially expressed genes in the motor cortex of HD brains (revealed by PSEA).
Annotation cluster 1 of neuronally DE genes in HD cortex (Table 3) is characterized by genes with plasma membrane-associated functions. This group includes G protein-coupled receptor 176 (GPR176), ADAM metallopeptidase domain 23 (ADAM23), synaptic vesicle glycoprotein 2B (SV2B), and DCLK1, but also RAB9B, STX1B and SCAMP5. Progressive abnormalities in SV2 expression in skeletal muscle and neuromuscular junctions have been previously reported in a mouse model of HD (Ribchester et al., ). DCLK1 is involved in cortical development (Sossey-Alaoui and Srivastava, ) and has been associated with schizophrenia and attention deficit/hyperactivity disorders (Havik et al., ). ADAM23 is a cell-cell adhesion protein highly expressed in the nervous system (Goldsmith et al., ) and suspected to regulate neuronal differentiation (Wang et al., ).
Functional annotation cluster analyses in PD brain find mitochondrion-associated molecules
Within the PD datasets, genes encompassing a variety of functions previously associated with PD were identified as DE, including pathways common to a number of different neurodegenerative diseases, such as HD and Alzheimer's disease (AD) (Table S8, Annotation cluster 4).
Functional annotation clustering analysis of genes DE in PD cortical neurons exhibited the highest complexity of enriched elements. Among these was an abundance of purine nucleotide binding-related genes (Annotation clusters 1, and 3). The cortical neuron purine binding nucleotide cluster comprises 26 DE genes, including several tubulin genes (TUBB2A, TUBG1, TUBA1B). Annotation clusters 2 and 5 include many terms associated with microtubules and tubulin, reflecting that abnormalities in microtubule dynamics have also been previously implicated in PD (reviewed in Feng, ).
Several lines of evidence have jointly supported causal links between changes in mitochondrial energetics and function and neuron-specific degeneration in PD (Jin et al., ; Narendra et al., ; Schapira, ; Van Laar and Berman, ). Consistent with this idea, oxidative phosphorylation, mitochondrial biological processes and mitochondrial localization were evident in the PD cortical neuron DE (Table S8, Annotation cluster 4), being represented by the mitochondrial inner membrane protein (IMMT), NADH dehydrogenase (ubiquinone) 1 subcomplex unknown-2 (NDUFC2) or cytochrome c oxidase subunits 4 isoform 1 and 5a (COX4I1 and COX5A). Changes in COX gene transcription has been purported to reflect cellular levels of oxidative stress (Roemgens et al., ) and affect cytochrome C oxidase activity (Castello et al., ). Interestingly, COX4I1 and COX5A were also found DE in the microglial PD PSEA data (Table S4). Microglial cells are specialized phagocytes that react to neuronal injury or damage (Glass et al., ) and can release neurotoxic reactive oxygen species under certain conditions (Block et al., ). Together with the fact that dopaminergic neurons are more sensitive to oxidative stress compared with other types of neurons (Block et al., ), changes in cytochrome activity in neurons or microglia might have a proximal effect on the development of PD (Chaturvedi and Beal, ).
Kinase genes, including selected mitogen-activated protein kinase-related genes (MAP2K1, MAP2K4, MAPK10), were well-represented within neurons in the PD cortex (Table S8 Annotation cluster 3). During neuronal injury various MAPKs can be activated in relation with effects on cellular respiration, transport, release of reactive oxygen species, mitophagy and apoptosis (Dagda et al., ). DE kinases also included the calcium/calmodulin-dependent protein kinase II beta (CAMK2B), known to important for synaptic plasticity and memory (Shonesy et al., ) and a brain-enriched p21-activated kinase (PAK7), as well as DCLK1.
Network analyses based on coregulation and protein-protein interaction highlight autophagy-related DE genes in PD neurons
Analyses using publically available data of coregulation and PPIs were undertaken to provide a complementary way to identify functional groups of genes within lists of identified DE gene lists. Coregulation of genes was used to initially construct DE gene networks, to which we added shared DE gene (protein) interacting proteins to potentially identify common targets or regulators of DE genes (proteins). Data from CNS cell-type-specific expression data was also utilized. Together these approaches increased insight into the nature of a given network's function.
One particularly well-populated gene network, of DE genes in PD putamen neurons, is illustrated in Figure 3. This network shows strong representation of autophagy-related processes. Autophagy is a highly evolutionarily conserved process carried out by the endosomal-lysosomal system to regulate protein and organelle turnover via targeted lysosomal degradation. There is increasing evidence that abnormalities in autophagy may contribute to neurodegeneration in HD, PD and AD (Lynch-Day et al., ). In particular, many proteins related to PD have specific roles in the regulation of autophagy and/or mitophagy (the clearance of mitochondrial components by autophagy) (reviewed in De Vries and Przedborski, ). There is clear evidence that reduced autophagy can lead to PD-linked phenomena including accumulation of α-synuclein, mitochondrial dysfunction and neuronal death (reviewed in Zhang et al., ).
Figure 3
The autophagy-related network illustrated in Figure 3 prominently features GABARAPL1, an autophagy gene 8 (ATG8) homolog, which was decreased in both the substantia nigra and putamen in PD brains. GABARAPL1 is the most highly expressed ATG8 homolog in the nervous system and it encodes a key autophagy protein that associates with autophagic vesicles (Chakrama et al., ). Its expression is limited to neuronal cells, and it is particularly highly expressed in the substantia nigra pars compacta, the region most affected by Parkinson's disease (Le Grand et al., ). In the neuronal putamen DE gene network, GABARAPL1 expression was coregulated with another highly expressed neuronal gene, Malate Dehydrogenase 1, NAD (MDH1). MDH1 is important in transporting NADH equivalents across the mitochondrial membrane and also interacts with the ubiquitin ligase PARKIN, encoded by PARK2 (Cookson, ; Scarffe et al., ). PARKIN is known to work together with PINK1 to promote mitophagy (Scarffe et al., ). Another mitochondrial gene, brain expressed, X-linked 1 (BEX1) (Xiao et al., ) interacts with the p75 neurotrophin receptor (Vilar et al., ) and is upregulated in axonal injury (Khazaei et al., ). Other genes in this network also play roles in synaptic vesicle exocyotosis [Regulator Of G-Protein Signaling 7 (RGS7)], regulation of apoptosis [Thymocyte Nuclear Protein 1 (THYN1/THY28) and Modulator of apoptosis protein 1 (MOAP1)] (Toyota et al., ), and α-synuclein aggregation [Secretogranin V (7B2 Protein) (SCG5)] (Helwig et al., ). Moreover, the protein products of 7 of the 11 genes in the putamen DE list interact with Ubiquitin (UBC) [Biogrid (http://thebiogrid.org/)]. GABARAPL1 and TSPYL1 proteins both interact with sirtuin 1 (SIRT1), a NAD-dependent deacetylase attributed with neuroprotecive activities in PD, AD, and HD (reviewed in Herskovits and Guarente, ), which is required for resveratrol-mediated induction of autophagy (Wu et al., ).
Notably, 6 of the 11 genes decreased with PD in neurons within the putamen are also decreased in PD cortical neurons (BEX1, ATP6V1E1, RGS7, MDH1, THYN1, MOAP1). There were also expression changes shared between the putamen and substantia nigra, including the decreased expression of the autophagy-related gene GABARAPL1 and lysosome H+ transporting ATPase subunits (ATP6V1E1 and ATP6V1A in putamen and substantia nigra respectively). There were also trends toward DE of MDH1 (p = 0.06), MOAP1 (p = 0.113), and BEX1 (p = 0.232) in the substantia nigra. It is also noteworthy that SNARE and NSF proteins (found decreased by PSEA and in LMD studies of PD substantia nigra neurons, see above) have been recently implicated in autophagy (Moreau et al., ) in addition to their better characterized function of being essential for vesicular fusion at the plasma membrane (Sudhof, ).
Summary and conclusions
Our study has further demonstrated the applicability and utility of PSEA to refine analyses of interesting human disease datasets. These further demonstrate the technical soundness of the method and show solutions for applying PSEA in cases where modeling all resident cell populations simultaneously is unfeasible. Most importantly, we show how PSEA can be applied to generate and refine hypotheses regarding the etiopathology of human neurological disorders, thereby contributing to the larger efforts to find new therapies. Our PSEA analyses were able to bring cell-type-specific disease pathways into view in this study. Findings in PD neurons supported the growing evidence that autophagy is an important aspect of PD etiology and identify additional potential contributors to autophagic and mitophagic dysfunction. Together with the identification of NSF as a candidate PD susceptibility gene our data suggest NSF as a strong candidate for further analysis. In HD neurons, both expected and novel facets of endosomal and plasma membrane signaling processes showed dysregulation. Moreover, the fact DCLK1 was detected as DE in both HD and PD neurons indicates that its potential involvement in neurodegenerative processes should be carefully considered.
It will be interesting in subsequent work to apply PSEA to other diseases and tissues. Moreover, we look forward to applying it to other data types, such as proteomic or metabolomic data, in which complementary insights into disease-related processes can be detected.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
We would like to thank the International Neuroscience Coordinating Facility (INCF) and the Center for Integrative and Translational Genomics of the University of Tennessee Health Science Center, Memphis, TN, USA for funding the INCF Short Course on Neuroinformatics, Neurogenomics and Brain Disease which brought us together for this project. This work was also funded by the University of Leicester (Ruth Luthi-Carter, Alberto Capurro). Alberto Capurro thanks Alexandre Kuhn (Agency for Science, Technology and Research, Singapore) and Marcelo Segura (Univ. College London, U.K.) for useful discussions about PSEA. Thanks to Paul Pavlidis (Univ. of British Colombia) for providing the human coexpression network data. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fnins.2014.00441/abstract
References
1
AkaikeH. (1974). A new look at the statistical model identification. Autom. Control IEEE Trans. 19, 716–723. 10.1109/TAC.1974.1100705
2
AlbinR. L.YoungA. B.PenneyJ. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375.
3
BarrettT.WilhiteS. E.LedouxP.EvangelistaC.KimI. F.TomashevskyM.et al. (2013). NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 41, D991–995. 10.1093/nar/gks1193
4
BatesG.HarperP. S.JonesL. (2002). Huntington's Disease. Oxford, UK: Oxford University Press.
5
BlockM. L.ZeccaL.HongJ. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57–69. 10.1038/nrn2038
6
CahoyJ. D.EmeryB.KaushalA.FooL. C.ZamanianJ. L.ChristophersonK. S.et al. (2008). A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28, 264–278. 10.1523/JNEUROSCI.4178-07.2008
7
CastelloP. R.WooD. K.BallK.WojcikJ.LiuL.PoytonR. O. (2008). Oxygen-regulated isoforms of cytochrome c oxidase have differential effects on its nitric oxide production and on hypoxic signaling. Proc. Natl. Acad. Sci. U.S.A. 105, 8203–8208. 10.1073/pnas.0709461105
8
CastermansD.VoldersK.CrepelA.BackxL.De VosR.FresonK.et al. (2010). SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum. Mol. Genet. 19, 1368–1378. 10.1093/hmg/ddq013
9
ChakramaF. Z.Seguin-PyS.Le GrandJ. N.FraichardA.Delage-MourrouxR.DespouyG.et al. (2010). GABARAPL1 (GEC1) associates with autophagic vesicles. Autophagy6, 495–505. 10.4161/auto.6.4.11819
10
ChaturvediR. K.BealM. F. (2013). Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci. 55, 101–114. 10.1016/j.mcn.2012.11.011
11
CooksonM. R. (2012). Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb. Perspect. Med. 2:a009415. 10.1101/cshperspect.a009415
12
DagdaR. K.ZhuJ.ChuC. T. (2009). Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion9, 289–298. 10.1016/j.mito.2009.06.001
13
DauerW.PrzedborskiS. (2003). Parkinson's disease: mechanisms and models. Neuron39, 889–909. 10.1016/S0896-6273(03)00568-3
14
De VriesR. L.PrzedborskiS. (2013). Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol. Cell. Neurosci. 55, 37–43. 10.1016/j.mcn.2012.07.008
15
DicksonD. W. (2012). Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med. 2:a009258. 10.1101/cshperspect.a009258
16
DijkmansT. F.Van HooijdonkL. W. A.FitzsimonsC. P.VreugdenhilE. (2010). The doublecortin gene family and disorders of neuronal structure. Cent. Nerv. Syst. Agents Med. Chem. 10, 32–46. 10.2174/187152410790780118
17
DoyleJ. P.DoughertyJ. D.HeimanM.SchmidtE. F.StevensT. R.MaG.et al. (2008). Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell135, 749–762. 10.1016/j.cell.2008.10.029
18
ElstnerM.MorrisC. M.HeimK.BenderA.MehtaD.JarosE.et al. (2011). Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol. 122, 75–86. 10.1007/s00401-011-0828-9
19
FengJ. (2006). Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist12, 469–476. 10.1177/1073858406293853
20
GautierL.CopeL.BolstadB. M.IrizarryR. A. (2004). Affy–analysis of affymetrix genechip data at the probe level. Bioinformatics20, 307–315. 10.1093/bioinformatics/btg405
21
GentlemanR. C.CareyV. J.BatesD. M.BolstadB.DettlingM.DudoitS.et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80. 10.1186/gb-2004-5-10-r80
22
GilJ. M.RegoA. C. (2008). Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27, 2803–2820. 10.1111/j.1460-9568.2008.06310.x
23
GlassC. K.SaijoK.WinnerB.MarchettoM. C.GageF. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell140, 918–934. 10.1016/j.cell.2010.02.016
24
GoldsmithA. P.GossageS. J.Ffrench-ConstantC. (2004). ADAM23 is a cell-surface glycoprotein expressed by central nervous system neurons. J. Neurosci. Res. 78, 647–658. 10.1002/jnr.20320
25
GrayK. A.DaughertyL. C.GordonS. M.SealR. L.WrightM. W.BrufordE. A. (2013). Genenames.org: the HGNC resources in 2013. Nucleic Acids Res. 41, D545–D552. 10.1093/nar/gks1066
26
HavikB.DegenhardtF. A.JohanssonS.FernandesC. P.HinneyA.ScheragA.et al. (2012). DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLoS ONE7:e35424. 10.1371/journal.pone.0035424
27
HelwigM.HoshinoA.BerridgeC.LeeS. N.LorenzenN.OtzenD. E.et al. (2013). The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J. Biol. Chem. 288, 1114–1124. 10.1074/jbc.M112.417071
28
HerskovitsA. Z.GuarenteL. (2014). SIRT1 in neurodevelopment and brain senescence. Neuron81, 471–483. 10.1016/j.neuron.2014.01.028
29
HodgesA.StrandA. D.AragakiA. K.KuhnA.SengstagT.HughesG.et al. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965–977. 10.1093/hmg/ddl013
30
Huang DaW.ShermanB. T.LempickiR. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57. 10.1038/nprot.2008.211
31
JinJ.HuletteC.WangY.ZhangT.PanC.WadhwaR.et al. (2006). Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics5, 1193–1204. 10.1074/mcp.M500382-MCP200
32
KaricA.TerzicR.KaricA.PeterlinB. (2011). Identifying candidate genes for Parkinson's disease by integrative genomics method. Biochem. Med. (Zagreb)21, 174–181. 10.11613/BM.2011.027
33
KhazaeiM. R.HalfterH.KarimzadehF.KooJ. H.MargolisF. L.YoungP. (2010). Bex1 is involved in the regeneration of axons after injury. J. Neurochem. 115, 910–920. 10.1111/j.1471-4159.2010.06960.x
34
KuhnA.CapurroA.Luthi-CarterR. (2015). Gene expression-based approaches to understanding huntington's disease and new tools for the interpretation of expression datasets, in Applied Neurogenomics, ed Jain Science booksK. K. (New York, NY: Springer), 64–81. 10.1007/978-1-4939-2247-5_2
35
KuhnA.KumarA.BeilinaA.DillmanA.CooksonM. R.SingletonA. B. (2012). Cell population-specific expression analysis of human cerebellum. BMC Genomics13:610. 10.1186/1471-2164-13-610
36
KuhnA.ThuD.WaldvogelH. J.FaullR. L.Luthi-CarterR. (2011). Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain. Nat. Methods8, 945–947. 10.1038/nmeth.1710
37
KumarK. R.LohmannK.KleinC. (2012). Genetics of Parkinson disease and other movement disorders. Curr. Opin. Neurol. 25, 466–474. 10.1097/WCO.0b013e3283547627
38
Le GrandJ. N.BonK.FraichardA.ZhangJ.JouvenotM.RisoldP. Y.et al. (2013). Specific distribution of the autophagic protein GABARAPL1/GEC1 in the developing and adult mouse brain and identification of neuronal populations expressing GABARAPL1/GEC1. PLoS ONE8:e63133. 10.1371/journal.pone.0063133
39
LiuX.ChengR.VerbitskyM.KisselevS.BrowneA.Mejia-SanatanaH.et al. (2011). Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet. 12:104. 10.1186/1471-2350-12-104
40
Lynch-DayM. A.MaoK.WangK.ZhaoM.KlionskyD. J. (2012). The role of autophagy in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a009357. 10.1101/cshperspect.a009357
41
MishimaT.FujiwaraT.SanadaM.KofujiT.Kanai-AzumaM.AkagawaK. (2014). Syntaxin 1B, but not syntaxin 1A, is necessary for the regulation of synaptic vesicle exocytosis and of the readily releasable pool at central synapses. PLoS ONE9:e90004. 10.1371/journal.pone.0090004
42
MistryM.GillisJ.PavlidisP. (2013). Meta-analysis of gene coexpression networks in the post-mortem prefrontal cortex of patients with schizophrenia and unaffected controls. BMC Neurosci. 14:105. 10.1186/1471-2202-14-105
43
MoreauK.RennaM.RubinszteinD. C. (2013). Connections between SNAREs and autophagy. Trends Biochem. Sci. 38, 57–63. 10.1016/j.tibs.2012.11.004
44
MudunuriU.CheA.YiM.StephensR. M. (2009). bioDBnet: the biological database network. Bioinformatics25, 555–556. 10.1093/bioinformatics/btn654
45
NarendraD.TanakaA.SuenD. F.YouleR. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. 10.1083/jcb.200809125
46
PihlstromL.AxelssonG.BjornaraK. A.DizdarN.FardellC.ForsgrenL.et al. (2013). Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiol. Aging34, 1708.e7–e13. 10.1016/j.neurobiolaging.2012.10.019
47
RibchesterR. R.ThomsonD.WoodN. I.HinksT.GillingwaterT. H.WishartT. M.et al. (2004). Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 20, 3092–3114. 10.1111/j.1460-9568.2004.03783.x
48
RoemgensA.SinghS.BeyerC.ArnoldS. (2011). Inducers of chemical hypoxia act in a gender- and brain region-specific manner on primary astrocyte viability and cytochrome C oxidase. Neurotox. Res. 20, 1–14. 10.1007/s12640-010-9213-z
49
ScarffeL. A.StevensD. A.DawsonV. L.DawsonT. M. (2014). Parkin and PINK1: much more than mitophagy. Trends Neurosci. 37, 315–324. 10.1016/j.tins.2014.03.004
50
SchapiraA. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97–109. 10.1016/S1474-4422(07)70327-7
51
ShonesyB. C.Jalan-SakrikarN.CavenerV. S.ColbranR. J. (2014). CaMKII: a molecular substrate for synaptic plasticity and memory. Prog. Mol. Biol. Transl. Sci. 122, 61–87. 10.1016/B978-0-12-420170-5.00003-9
52
SimunovicF.YiM.WangY.StephensR.SonntagK. C. (2010). Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE5:e8856. 10.1371/journal.pone.0008856
53
SmootM. E.OnoK.RuscheinskiJ.WangP. L.IdekerT. (2011). Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics27, 431–432. 10.1093/bioinformatics/btq675
54
SmythG. K. (2005). Limma: linear models for microarray data, in Bioinformatics and Computational Biology Solutions using R and Bioconductor, eds GentlemanR.CareyV.DudoitS.IrizarryR.HuberW. (New York, NY: Springer), 397–420. 10.1007/0-387-29362-0_23
55
Sossey-AlaouiK.SrivastavaA. K. (1999). DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar to doublecortin (DCX). Genomics56, 121–126. 10.1006/geno.1998.5718
56
SprootenE.KnowlesE. E.McKayD. R.GoringH. H.CurranJ. E.KentJ. W.Jr.et al. (2014). Common genetic variants and gene expression associated with white matter microstructure in the human brain. Neuroimage97, 252–261. 10.1016/j.neuroimage.2014.04.021
57
StarkC.BreitkreutzB. J.RegulyT.BoucherL.BreitkreutzA.TyersM. (2006). BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535–D539. 10.1093/nar/gkj109
58
SudhofT. C. (1995). The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature375, 645–653. 10.1038/375645a0
59
TangB.SeredeninaT.CoppolaG.KuhnA.GeschwindD. H.Luthi-CarterR.et al. (2011). Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol. Dis. 42, 459–467. 10.1016/j.nbd.2011.02.008
60
The Huntingtons Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell72, 971–983.
61
ToyotaH.JiangX. Z.AsakuraH.MizuguchiJ. (2012). Thy28 partially prevents apoptosis induction following engagement of membrane immunoglobulin in WEHI-231 B lymphoma cells. Cell. Mol. Biol. Lett. 17, 36–48. 10.2478/s11658-011-0034-8
62
Van LaarV. S.BermanS. B. (2009). Mitochondrial dynamics in Parkinson's disease. Exp. Neurol. 218, 247–256. 10.1016/j.expneurol.2009.03.019
63
VilarM.Murillo-CarreteroM.MiraH.MagnussonK.BessetV.IbanezC. F. (2006). Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J. 25, 1219–1230. 10.1038/sj.emboj.7601017
64
VonsattelJ. P.KellerC.Cortes RamirezE. P. (2011). Huntington's disease - neuropathology. Handb. Clin. Neurol. 100, 83–100. 10.1016/B978-0-444-52014-2.00004-5
65
WangY.SunY.QiaoS. (2012). ADAM23 knockdown promotes neuronal differentiation of P19 embryonal carcinoma cells by up-regulating P27KIP1 expression. Cell Biol. Int. 36, 1275–1279. 10.1042/CBI20120154
66
WarsowG.GreberB.FalkS. S.HarderC.SiatkowskiM.SchordanS.et al. (2010). ExprEssence–revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst. Biol. 4:164. 10.1186/1752-0509-4-164
67
WuY.LiX.ZhuJ. X.XieW.LeW.FanZ.et al. (2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 19, 163–174. 10.1159/000328516
68
XiaoQ.HuY.LiuY.WangZ.GengH.HuL.et al. (2014). BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2. PLoS ONE9:e91782. 10.1371/journal.pone.0091782
69
ZhangH.DuanC.YangH. (2014). Defective autophagy in Parkinson's disease: lessons from genetics. Mol. Neurobiol. [Epub ahead of print]. 10.1007/s12035-014-8787-5
70
ZhangY.JamesM.MiddletonF. A.DavisR. L. (2005). Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 137B, 5–16. 10.1002/ajmg.b.30195
71
ZhaoH.KimY.ParkJ.ParkD.LeeS. E.ChangI.et al. (2014). SCAMP5 Plays a critical role in synaptic vesicle endocytosis during high neuronal activity. J. Neurosci. 34, 10085–10095. 10.1523/JNEUROSCI.2156-14.2014
72
ZhengB.LiaoZ.LocascioJ. J.LesniakK. A.RoderickS. S.WattM. L.et al. (2010). PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73. 10.1126/scitranslmed.3001059
Summary
Keywords
computational deconvolution, Huntington's disease, Parkinson's disease, autophagy, microarray, transcriptomic analysis
Citation
Capurro A, Bodea L-G, Schaefer P, Luthi-Carter R and Perreau VM (2015) Computational deconvolution of genome wide expression data from Parkinson's and Huntington's disease brain tissues using population-specific expression analysis. Front. Neurosci. 8:441. doi: 10.3389/fnins.2014.00441
Received
08 September 2014
Accepted
15 December 2014
Published
09 January 2015
Volume
8 - 2014
Edited by
Rupert W. Overall, Technische Universität Dresden, Germany
Reviewed by
Sulev Kõks, University of Tartu, Estonia; Travis Dunckley, Translational Genomics Research Institute, USA; Anna Natalia Grzyb, German Center for Neurodegenerative Diseases (DZNE), Germany
Copyright
© 2015 Capurro, Bodea, Schaefer, Luthi-Carter and Perreau.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ruth Luthi-Carter, Department of Cell Physiology and Pharmacology, University of Leicester, Maurice Shock Building, University Road, PO Box 138, Leicester LE1 9HN, UK e-mail: relc3@leicester.ac.uk;
This article was submitted to Neurogenomics, a section of the journal Frontiers in Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.